DSE:BXPHARMA

Beximco Pharmaceuticals PLC. research

Reports on Beximco Pharmaceuticals PLC.

Company · Initiation · 29 Oct 2026

Beximco Pharmaceuticals: fair value BDT 99–218 as FY2026 EPS rises 30% to BDT 20.17

Fair value BDT 99–218 (base 179) against a price of BDT 143.7. Domestic brands, exports and a falling materials bill lift EPS to BDT 28.7 by FY2029F; governance volatility (beta 1.46) and a weaker taka are the risks.

Beximco Pharmaceuticals PLC (DSE: BXPHARMA) is Bangladesh's third-largest drug maker and a nine-time winner of the National Export Trophy (Gold), with US FDA-certified plants at Tongi and Kaliakoir and 18 FDA product approvals. On 28-Oct-2026 its board reported FY2026 consolidated EPS of BDT 20.17 (FY2025:…

Fair value ৳99–218 · price ৳143.70 (2026-10-29)

Peer comparisons and industry research covering Beximco Pharmaceuticals PLC.

Company · DSE:BEXIMCO · Conglomerate · Analysis · 29 Oct 2026

Beximco Ltd: no accounts since December 2024, factories shut and Tk 87bn of parent debt

Beximco Ltd's last statement shows H1 FY2025 revenue down 71% and a Tk 3,565m loss. Six reporting periods are overdue, and the share has fallen 82% since its floor was removed.

What it is. Bangladesh Export Import Company Ltd (Beximco Ltd) is the listed flagship of the Beximco Group. In its last annual report it was almost entirely a textile company: yarn, fabrics and related products were 98.5% of FY2024 sales of goods, with small IT-service…

All Bangladesh research →